

August 6, 2025

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

Sub.: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015: Glenmark Pharmaceuticals Ltd. (hereinafter referred as “the Company”)

The Company and its subsidiaries are involved in legal proceedings from time to time, consistent with the nature of the pharmaceutical industry. Certain matters may be resolved through settlement agreements, where appropriate.

The Company’s subsidiary, Glenmark Pharmaceuticals Inc., USA, (hereinafter referred to as “Glenmark USA”), is named in multiple antitrust and consumer protection lawsuits, including class actions, consolidated in the Eastern District of Pennsylvania, U.S. These relate to industry-wide allegations concerning price-fixing, market allocation, and related anticompetitive conduct. Plaintiffs include putative classes of direct purchasers, end-payers, and indirect purchasers of generic drugs, as well as numerous private, direct-action plaintiffs. Plaintiffs allege both individual drug-specific conspiracies and an “overarching” conspiracy among manufacturers of generic drugs in the United States. Glenmark USA continues to deny all allegations and has been defending these matters vigorously.

With a view to resolve this dispute and avoid uncertainty, Glenmark USA has agreed to enter into a settlement with the putative direct purchaser class, for a total of \$37.75 million (USD). The settlement is subject to approval by the court overseeing the litigation. The settlement is payable in two instalments, with \$11,100,000 (USD) due after preliminary approval by the Court and the second payment, \$26,650,000 (USD), due on or before April 1, 2026. The settlement makes clear that Glenmark USA denies each and every one of the allegations against it and the settlement is not on the basis of Glenmark USA having conceded or admitted any liability or illegality.

This is for your information and dissemination.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com